InflaRx N.V. IFRX

InflaRx N.V. announced a virtual Capital Markets Day on Nov 3, 2026, from 8:00 AM EST (2:00 PM CET) to about 9:00 AM EST (3:00 PM CET). The schedule was shifted to better align with clinical development planning in ANCA-associated vasculitis (AAV). The program will feature InflaRx management and invited external experts, including Peter A. Merkel, MD, MPH, and Prof. Dr. Jörg Köhl, and will cover the evolving AAV treatment landscape and unmet need, as well as izicopan's chemistry, metabolic properties and potential safety advantages that could improve on current AAV standards of care. An overview of InflaRx's development strategy in AAV and anticipated clinical programs will be provided, followed by a Q&A. Merkel is a rheumatology and vasculitis expert; Köhl is a leading complement scientist. The investor-focused event could influence sentiment and clarify strategy, but no new clinical data or approvals are announced.

InflaRx N.V. released second quarter 2026 financial results and outlined key achievements plus expected milestones. Quarterly results and milestone updates can shift near-term sentiment and financial outlook but rarely redefine long-term trajectory.

InflaRx evaluates expanded ANCA-associated vasculitis strategy in Europe after EMA recommends Tavneos. EMA action on Tavneos forces InflaRx to reassess its European AAV plans and may shift competitive positioning.

InflaRx releases investor update positioning izicopan as the central asset in its pipeline for ANCA-associated vasculitis (AAV) and renal diseases, emphasizing its potential to drive clinical and commercial progress. Izicopan's elevation to centerpiece status in AAV and renal disease pipeline signals major strategic focus with high potential to enhance clinical outcomes and investor sentiment.

InflaRx N.V. (IFRX) closed a $150 million underwritten public offering of ordinary shares. A $150 million capital raise via share offering provides significant funding to support clinical trials and extend operational runway.

InflaRx N.V. (IFRX) has regained compliance with Nasdaq listing requirements after addressing prior deficiencies. Regaining Nasdaq compliance eliminates delisting risk and enhances investor confidence in the company's market stability.

InflaRx N.V. (IFRX) priced a $150 million underwritten offering of ordinary shares. $150 million share offering injects major capital for operations and trials but dilutes shareholders, significantly altering financial trajectory and market sentiment.

InflaRx N.V. (IFRX) announces advancement of izicopan in ANCA-associated vasculitis and select renal diseases. Advancement of lead complement inhibitor izicopan into further development for vasculitis and renal indications marks a significant clinical milestone boosting pipeline value.

InflaRx N.V. (IFRX) reports favorable reactive metabolite profile for izicopan in human liver microsomes, indicating minimal formation of reactive metabolites and low risk of idiosyncratic drug-induced liver injury. Favorable preclinical safety data for lead candidate izicopan de-risks liver toxicity concerns and supports clinical advancement, with moderately noticeable impact on development trajectory and market sentiment.

InflaRx N.V. (IFRX) regained compliance with Nasdaq's minimum bid price requirement after implementing a strategy that raised its stock price above $1.00 for 10 consecutive trading days. Regaining Nasdaq compliance removes delisting risk and supports short-term market stability and investor sentiment.

InflaRx reports new mechanistic data for izicopan supporting its potential as a best-in-class C5aR inhibitor. New mechanistic data bolsters izicopan's competitive positioning in the C5aR inhibitor space, likely enhancing investor sentiment and pipeline prospects.

InflaRx presented clinical activity data of vilobelimab in pyoderma gangrenosum as a late-breaker oral at the 2026 American Academy of Dermatology Annual Meeting. Late-breaker oral presentation of positive vilobelimab data in pyoderma gangrenosum at AAD boosts InflaRx pipeline credibility and investor sentiment significantly.

InflaRx N.V. (IFRX) reported full year 2025 financial results, highlighted key achievements, and outlined expected milestones. Full year results combined with achievements and milestones signal major strategic progress likely to alter trajectory and investor sentiment.

InflaRx N.V. (IFRX) announces late-breaker oral presentation on vilobelimab Phase 3 results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting. Late-breaker oral presentation of Phase 3 vilobelimab results at a major dermatology meeting signals potential regulatory and commercial breakthroughs for InflaRx's lead asset.

InflaRx N.V. (IFRX) received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement, with its closing bid price below $1.00 for 30 consecutive business days, triggering a 180-day compliance period. Nasdaq deficiency notice for minimum bid price introduces delisting risk, moderately impacting investor sentiment and short-term market performance.

InflaRx showcased izicopan data for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) while streamlining its C5aR strategy at the Oppenheimer Conference. Showcasing clinical data on izicopan and streamlining C5aR strategy represent major pipeline advancements likely to positively influence investor sentiment and stock performance.

InflaRx N.V. highlighted data from its Izicopan HS study and outlined plans for a Phase 2b trial at the Guggenheim Summit. The company also announced a 30% reduction in costs to enhance operational efficiency and focus on key projects. The announcement of significant cost cuts and a new Phase 2b trial for Izicopan HS indicates a strategic shift that could positively impact future performance.

InflaRx N.V. is urged to manage its cash reserves prudently as it navigates financial challenges and seeks to advance its clinical programs. The company faces pressure to optimize its spending while pursuing strategic initiatives that could enhance its market position and investor confidence. Effective cash management is critical for sustaining operations and funding future growth opportunities. Cash management is crucial for maintaining operations and could influence financial performance.

InflaRx N.V. has announced a strategic focus on capital-efficient execution with its lead product, Izicopan, aiming for near-term value creation. The company plans to streamline operations and prioritize initiatives that enhance financial performance and market positioning, signaling a commitment to optimizing resources while advancing its therapeutic pipeline. The strategic focus on capital efficiency and product development is likely to significantly impact the company's future performance and investor sentiment.

InflaRx N.V. provided an update on the Phase 3 data analyses for its drug Vilobelimab, aimed at treating Pyoderma Gangrenosum. The company highlighted positive results, indicating the drug's potential effectiveness in managing this severe skin condition. Further details on the study's outcomes and implications for future development were shared, emphasizing the importance of these findings for patients and the company's pipeline. Positive Phase 3 data for Vilobelimab could significantly enhance InflaRx's market position and investor sentiment.

InflaRx N.V. announced that the international nonproprietary name for its drug INF904 will be 'Izicopan'. This designation is a significant step in the drug's development and regulatory process, potentially enhancing its visibility and acceptance in the global market. The announcement of the international nonproprietary name for Izicopan is a significant milestone that could positively influence market perception and the drug's future prospects.

The Microscopic Polyangiitis Market Research Report for 2025-2035 provides a competitive analysis of key players including Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, and Celltrion. It outlines market dynamics, potential growth opportunities, and strategic positioning of these companies in the treatment landscape for microscopic polyangiitis. The competitive analysis may moderately influence InflaRx's positioning and market sentiment in the context of its peers.

InflaRx N.V. (IFRX) shares surged by 17.7% following positive results from its Phase 2a study of INF904, a treatment for autoimmune diseases. The study demonstrated promising efficacy and safety profiles, leading to increased investor confidence and market interest in the company's future prospects. Analysts are optimistic about the potential for INF904 to advance in clinical development, which could significantly impact InflaRx's market position and financial performance. Positive Phase 2a results for INF904 could significantly influence InflaRx's future performance and investor sentiment.

InflaRx N.V. announced positive Phase 2a clinical trial results for its drug INF904, targeting Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU). The data demonstrated significant efficacy and safety, suggesting potential for INF904 in treating these conditions. The company plans to advance the development of INF904 based on these encouraging results. Positive Phase 2a data for INF904 could significantly enhance InflaRx's product pipeline and market position in treating HS and CSU.

InflaRx N.V. (IFRX) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect investor sentiment or reactions to recent developments related to the company's operations or market position. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

InflaRx N.V. is set to announce topline data from its Phase 2a clinical trial of INF904, targeting conditions such as Hidradenitis Suppurativa and Chronic Spontaneous Urticaria. This announcement is anticipated to provide insights into the drug's efficacy and safety, potentially influencing the company's future development strategies and market position. The upcoming data release could significantly impact InflaRx's strategic direction and investor sentiment regarding its product pipeline.

InflaRx N.V. has regained compliance with the Nasdaq minimum bid price requirement after its stock price rose above the $1 threshold for 10 consecutive trading days. This development follows a period of non-compliance, which could have led to delisting. The company expressed satisfaction with this outcome, emphasizing its commitment to maintaining its listing on the exchange. Regaining compliance with Nasdaq requirements helps stabilize investor confidence and supports the company's market position.

InflaRx N.V. reported a loss for Q2, falling short of revenue estimates. The company's financial performance reflects ongoing challenges in its operations, impacting investor sentiment and future outlook. The missed revenue estimates indicate potential challenges in financial performance and market positioning.

InflaRx N.V. reported its financial results for the second quarter of 2025, highlighting key metrics and updates on its business operations. The company provided insights into its ongoing projects and strategic initiatives, indicating progress in its clinical development pipeline. Financial performance showed trends that may influence future growth and investor sentiment. The financial results and business updates indicate moderate influence on the company's future performance and market positioning.

InflaRx N.V. is focusing on advancing its clinical programs and expanding its pipeline, particularly in the treatment of autoimmune diseases. The company is preparing for potential product launches and is actively engaging with regulatory bodies to ensure compliance and support for its growth plans. Financial performance remains a key area of focus, with ongoing efforts to secure funding and partnerships to bolster its market position. Significant strategic moves and potential product launches could alter the company's trajectory and investor sentiment.